Exdensur depemokimab 100 mg/mL Injection, Solution, 1 syringe — NDC 0173-0927-42 (Billing 00173-0927-42)
This is a package of 1 syringe of Exdensur depemokimab 100 mg/mL Injection, Solution from GlaxoSmithKline LLC, first listed with the FDA Dec 2025 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 0173-0927-42 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 0173 labeler · 0927 product · 42 package
- Package marketed since
- Dec 16, 2025
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 0173092742 2
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 088500
- GCN: 58631
- GPI-14 (Medi-Span): 4460403000E520
- HICL (First Databank): 051066
- AHFS class code: 48:10.20.00
- RxCUI (RxNorm): 2729271
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 19, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Other systemic drugs for obstructive airway diseases class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
Depemokimab-ulaa injection is used to treat severe asthma. Depemokimab-ulaa is in a class of medications called monoclonal antibodies. It works by reducing a certain type of white blood cell that causes inflammation in airways.
Read the full MedlinePlus article ↗Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 19, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 00173-0927-42 You're viewing this Main listing | 1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE | 2025-12-16 | — | Active |
| 00173-0927-61 0173-0927-61 | 1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE | 2026-03-30 | — | Active |
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 00173-0927-61?
What NDC number is used to bill for this package of Exdensur depemokimab 100 mg/mL Injection, Solution?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Exdensur 100 mg/mLthis 00173-0927-42 | GlaxoSmithKline | 1 syringe | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Purple Book · refreshed Nov 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Why the date isn’t exact: Biosimilar timing can change because patents may be challenged, settled, licensed, added or removed, and litigation can move the real date earlier or later.
🛈 What do these terms mean?
- Biologic patent
- A patent the reference product’s maker has publicly listed. A biosimilar generally can’t launch until these expire — unless they’re invalidated or resolved in a settlement.
- Reference-product exclusivity
- A flat 12 years of FDA market protection from the biologic’s first licensure (the BPCIA). No biosimilar can be licensed before it ends, regardless of patents.
- Interchangeable exclusivity
- The first interchangeable biosimilar can earn a period as the only interchangeable version (pharmacists can substitute it without the prescriber).
- Earliest biosimilar (LOE)
- The latest of all the dates above — the soonest a biosimilar can realistically reach the market. Litigation and settlements can move it earlier.
Biologics have no small-molecule “generics” — competition comes from FDA-licensed biosimilars, tracked in the FDA Purple Book.
| Code | What it grants | Expires |
|---|---|---|
| RefProduct | Reference-product exclusivity (12-year, BPCIA) — no biosimilar can be licensed before this date | Dec 16, 2037 |
Is there a biosimilar for EXDENSUR 100 MG/ML SYRINGE?
Why do different websites show different biosimilar dates?
Can a biosimilar launch before the last patent expires?
What does “current Purple Book estimate” mean?
What does “FDA listed” mean?
What does a patent or protection date mean here?
Where does this data come from?
- FDA Purple Book · refreshed Nov 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII F7LTH1E20Y
Arginine hydrochloride is an amino acid salt used as a buffer and pH adjuster in medicines. It helps maintain the correct acidity level to keep the drug stable and effective.
-
UNII 7FLD91C86K
Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
-
UNII 4QD397987E
An amino acid used as a buffer and stabilizer in medications. It helps maintain the pH balance and protects the active drug from breaking down during storage and use.
-
UNII 1D5Q932XM6
An amino acid salt used in medicines as a buffer and pH regulator. It helps maintain the proper acidity level in liquid formulations to keep the drug stable and effective.
-
UNII 6OZP39ZG8H
Polysorbate 80 is a synthetic emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together in medications and improves how the product disperses in the body.
-
UNII 7YIN7J07X4
A natural sugar derived from plants and microorganisms. It acts as a filler to give the medication bulk and stability, and helps preserve the active ingredient during storage and manufacturing.
6 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 19, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from GlaxoSmithKline LLC labeler code 00173
- Zejula niraparib 200 mg Tablet, Film Coated NDC 0173-0912-13
- Blenrep belantamab mafodotin 50 mg/mL Injection, Powder, For Solution NDC 0173-0913-01
- Jesduvroq daprodustat 8 mg Tablet, Film Coated NDC 0173-0914-13
- Zejula niraparib 300 mg Tablet, Film Coated NDC 0173-0915-13
- Breo Ellipta fluticasone furoate and vilanterol trifenatate 50 ug; 25 ug Powder NDC 0173-0916-10
- Blujepa gepotidacin 750 mg Tablet, Film Coated NDC 0173-0922-38
- Valtrex valacyclovir hydrochloride 500 mg Tablet, Film Coated NDC 0173-0933-08
- Hibsago Bepirovirsen 150 mg/mL Injection, Solution NDC 0173-0941-39
- Wellbutrin SR bupropion hydrochloride 100 mg Tablet, Film Coated NDC 0173-0947-55
- Utebzi Tebipenem Pivoxil 300 mg Tablet, Film Coated NDC 0173-0956-76
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE EXDENSUR is indicated for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. Limitations of Use EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions ( 5.2 )] . EXDENSUR is an interleukin‑5 (IL‑5) antagonist, a monoclonal antibody (humanized immunoglobulin G1 [IgG1] kappa) indicated for add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.
( 1 ) Limitations of Use : Not for relief of acute bronchospasm or status asthmaticus. ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION The recommended dosage is 100 mg administered once every 6 months by subcutaneous injection into the upper arm, thigh, or abdomen. ( 2.1 ) • EXDENSUR should be administered by a healthcare provider. ( 2.2 ) • See full prescribing information for preparation and administration instructions. ( 2.2 )
2.1Recommended Dosage The recommended dosage is 100 mg once every 6 months administered by subcutaneous injection into the upper arm, thigh, or abdomen avoiding 2 inches (5 cm) around the navel [see Dosage and Administration ( 2.2 )] . Missed Dose(s) If a dose is missed, administer the missed dose as soon as possible and resume the once every 6‑month injection schedule from the date of when the missed dose was given.
2.2Preparation and Administration Instructions for EXDENSUR • EXDENSUR is for subcutaneous use only. • EXDENSUR should be administered by a healthcare provider. • Do not use EXDENSUR prefilled syringe if the security seal on the carton has been broken or if it has been dropped or damaged. Preparation Instructions 1. Remove the prefilled syringe from the refrigerator.
Holding the middle of the prefilled syringe, take it out from the tray and allow it to sit at room temperature for 30 minutes prior to injection. Do not warm EXDENSUR injection in any other way. Do not remove the needle cap until you are ready to inject.
Do not use the syringe if it has been left out of the carton for more than 8 hours. 2. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
EXDENSUR should be colorless to yellow to brown, clear to opalescent in color. Do not use EXDENSUR if the product exhibits discoloration, cloudiness, or particulate matter. It is normal to see an air bubble.
Do not expel the air bubble prior to administration. Do not shake the device. 3.
Choose the injection site; administer EXDENSUR into upper arm, thigh, or abdomen, avoiding the 2 inches (5 cm) around the navel. Do not give injections into areas where the skin is tender, bruised, red, or hard. Administration Instructions Figure 1.
EXDENSUR Prefilled Syringe Components 1. Pull Off the Gray Needle Cap Remove the gray needle cap from the syringe by pulling it straight off, away from the needle. Do not handle the syringe by the white plunger while removing the gray needle cap.
Do not put the gray needle cap back onto the syringe. Inject within 5 minutes after removing the gray needle cap. 2.
Position the Syringe at the Injection Site Use your free hand to gently pinch the skin around the cleaned injection site. Do not handle the syringe by the white plunger while inserting the needle into the pinched skin. Hold the middle of the syringe and insert the entire needle into the pinched skin at a 45 degree angle, as shown.
3. Start the Injection and Fully Press the White Plunger Slowly push down on the white plunger with your thumb to inject the full dose. Make sure the white plunger is pushed all the way down until the stopper reaches the bottom of the syringe and all of the medication is injected.
4. Slowly Lift Thumb After Injection Completes Slowly lift your thumb up. This will allow the white plunger to come up and the needle to automatically pull up (retract) into the needle guard.
After removing the syringe from the injection site, release the pinched skin. 5. Throw Away Dispose of used syringe according to local health and safety laws.
Figure 1 1. Pull Off the Gray Needle Cap 2. Position the Syringe at the Injection Site 3.
Start the Injection and Fully Press the White Plunger 4. Slowly Lift Thumb After Injection Completes
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Injection: 100 mg/mL of depemokimab‑ulaa as a colorless, yellow to brown, clear to opalescent solution in a single‑dose, prefilled syringe with needle guard. Injection: 100 mg/mL solution in a single‑dose, prefilled syringe with needle guard. ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS None. None. ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS • Hypersensitivity reactions, including anaphylaxis, can occur after administration of EXDENSUR. If a hypersensitivity reaction occurs, discontinue EXDENSUR and initiate appropriate therapy. ( 5.1 ) • Do not abruptly discontinue systemic or inhaled corticosteroids upon initiation of therapy with EXDENSUR.
Reduce corticosteroid dose gradually, if appropriate. ( 5.3 ) • Treat pre-existing helminth infections before initiating therapy with EXDENSUR. If patients become infected while receiving treatment with EXDENSUR and do not respond to anti‑helminth treatment, discontinue EXDENSUR until the parasitic infection resolves.
( 5.4 )
5.1Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, can occur following administration of EXDENSUR. If a hypersensitivity reaction occurs, discontinue EXDENSUR and initiate appropriate therapy.
5.2Acute Asthma Symptoms or Deteriorating Disease EXDENSUR should not be used to treat acute asthma symptoms or acute exacerbations. Do not use EXDENSUR to treat acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with EXDENSUR.
5.3Risk Associated With Abrupt Reduction of Corticosteroid Dosage Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy. Do not abruptly discontinue systemic or inhaled corticosteroids upon initiation of EXDENSUR therapy. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the supervision of a healthcare provider.
5.4Parasitic (Helminth) Infection Eosinophils may be involved in the immunological response to some helminth infections. Patients with pre‑existing helminth infections were excluded from participation in the clinical trials. It is unknown if EXDENSUR will influence a patient’s response against parasitic infections.
Patients with pre‑existing helminth infections should be treated for their infection prior to initiation of EXDENSUR therapy. If patients become infected while receiving treatment with EXDENSUR and do not respond to anti‑helminth treatment, discontinue treatment with EXDENSUR until the infection resolves.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: • Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] . The most common adverse reactions (incidence ≥4%) are upper respiratory tract infection, allergic rhinitis, influenza, arthralgia, and pharyngitis. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of EXDENSUR was based on a pooled safety population from 2 replicate, randomized, double‑blind, parallel‑group, placebo‑controlled, multicenter clinical trials (SWIFT‑1 and SWIFT‑2) of 52 weeks duration. The 2 trials included 762 adult and pediatric patients 12 years of age and older with asthma, who received either EXDENSUR 100 mg or placebo administered subcutaneously once every 6 months in addition to their existing background medications for asthma [see Clinical Studies ( 14 )] .
A total of 475 patients received 2 doses of EXDENSUR 100 mg in these trials. Adverse reactions with EXDENSUR with incidence of ≥4% are shown in Table 1 . Table 1.
Adverse Reactions With EXDENSUR With an Incidence ≥4% and More Common Than Placebo in Patients With Asthma Adverse Reaction EXDENSUR (N = 501) n (%) Placebo (N = 261) n (%) Upper respiratory tract infection 46 (9) 20 (8) Allergic rhinitis 29 (6) 7 (3) Influenza 24 (5) 11 (4) Arthralgia 19 (4) 8 (3) Pharyngitis 18 (4) 3 (1) Specific Adverse Reactions Injection Site Reactions: In the pooled safety population (SWIFT‑1 and SWIFT‑2), in which EXDENSUR was administered by a healthcare provider, injection site reactions (e.g., erythema, swelling, and itching) occurred in 7 (1%) and 2 (<1%) patients receiving EXDENSUR and placebo, respectively.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS Pregnancy: EXDENSUR can cross the placenta during pregnancy and the presence of the YTE modification may prolong and increase exposure to the infant exposed in utero. The impact of EXDENSUR transmission to the fetus should be considered. ( 8.1 )
8.1Pregnancy Risk Summary Available data from clinical trials with EXDENSUR use in pregnant women are insufficient to identify a drug‑associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with asthma in pregnancy (see Clinical Considerations). Transport of endogenous immunoglobulin G (IgG) antibodies and monoclonal antibodies, such as depemokimab‑ulaa, across the placenta increases as pregnancy progresses and peaks during the third trimester.
The impact of the YTE modification on placental transfer is uncertain [see Clinical Pharmacology ( 12.1 )] ; however, the presence of the YTE modification may lead to prolonged and increased exposure of the infant exposed in utero , and the potential of clinical impact is unknown and should be considered. No treatment‑related effects on embryofetal or postnatal development have been shown in animal studies targeting interleukin‑5 (IL‑5) signaling pathways (see Data) . The background risk of major birth defects and miscarriage for the indicated population(s) is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Pregnant women exposed to EXDENSUR, or their healthcare providers, should report EXDENSUR exposure by calling 1‑888‑825‑5249.
Clinical Considerations Disease ‑ Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately controlled asthma, evidence demonstrates that there is an increased risk of preeclampsia in the mother, and prematurity, low birth weight, and small for gestational age in the neonate. The level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control. Data Animal Data: Reproductive toxicology studies have not been conducted with depemokimab‑ulaa.
In animal studies targeting the IL‑5 signaling pathway with a related biologic product without the YTE modification, there were no developmental effects observed [see Nonclinical Toxicology ( 13 )] . Embryofetal development of IL‑5 deficient mice has been reported to be generally unaffected relative to wild‑type mice.
8.2Lactation Risk Summary There are no data on the presence of depemokimab‑ulaa in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. However, depemokimab‑ulaa is a humanized monoclonal antibody (immunoglobulin G1 [IgG1] kappa), and maternal IgG is present in human milk in small amounts. The effects of local gastrointestinal exposure and the extent of systemic exposure in the breastfed infant to EXDENSUR are unknown.
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for EXDENSUR, and any potential adverse effects on the breastfed child from EXDENSUR or from the underlying maternal condition.
8.4Pediatric Use Asthma The safety and effectiveness of EXDENSUR for add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype have been established in pediatric patients aged 12 years and older. Use of EXDENSUR for this indication is supported by evidence from adequate and well‑controlled trials (SWIFT‑1 and SWIFT‑2) in adults and pediatric patients aged 12 years and older, and pharmacokinetic data in pediatric patients aged 12 years and older. A total of 30 pediatric patients aged 12 to 17 years with asthma were enrolled in the SWIFT‑1 and SWIFT‑2 trials, of whom 15 received EXDENSUR 100 mg.
Pharmaco… [Excerpted — this section continues on DailyMed.]
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary Available data from clinical trials with EXDENSUR use in pregnant women are insufficient to identify a drug‑associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with asthma in pregnancy (see Clinical Considerations). Transport of endogenous immunoglobulin G (IgG) antibodies and monoclonal antibodies, such as depemokimab‑ulaa, across the placenta increases as pregnancy progresses and peaks during the third trimester.
The impact of the YTE modification on placental transfer is uncertain [see Clinical Pharmacology ( 12.1 )] ; however, the presence of the YTE modification may lead to prolonged and increased exposure of the infant exposed in utero , and the potential of clinical impact is unknown and should be considered. No treatment‑related effects on embryofetal or postnatal development have been shown in animal studies targeting interleukin‑5 (IL‑5) signaling pathways (see Data) . The background risk of major birth defects and miscarriage for the indicated population(s) is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Pregnant women exposed to EXDENSUR, or their healthcare providers, should report EXDENSUR exposure by calling 1‑888‑825‑5249.
Clinical Considerations Disease ‑ Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately controlled asthma, evidence demonstrates that there is an increased risk of preeclampsia in the mother, and prematurity, low birth weight, and small for gestational age in the neonate. The level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control. Data Animal Data: Reproductive toxicology studies have not been conducted with depemokimab‑ulaa.
In animal studies targeting the IL‑5 signaling pathway with a related biologic product without the YTE modification, there were no developmental effects observed [see Nonclinical Toxicology ( 13 )] . Embryofetal development of IL‑5 deficient mice has been reported to be generally unaffected relative to wild‑type mice.
🧒 Pediatric Use ▾
8.4Pediatric Use Asthma The safety and effectiveness of EXDENSUR for add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype have been established in pediatric patients aged 12 years and older. Use of EXDENSUR for this indication is supported by evidence from adequate and well‑controlled trials (SWIFT‑1 and SWIFT‑2) in adults and pediatric patients aged 12 years and older, and pharmacokinetic data in pediatric patients aged 12 years and older. A total of 30 pediatric patients aged 12 to 17 years with asthma were enrolled in the SWIFT‑1 and SWIFT‑2 trials, of whom 15 received EXDENSUR 100 mg.
Pharmacokinetic and pharmacodynamic data have demonstrated no clinically significant differences in systemic exposure of depemokimab‑ulaa and reduction in blood eosinophil counts in pediatric patients aged 12 years and older compared to that observed in adults following administration of the recommended dosage of EXDENSUR. The safety of EXDENSUR in pediatric patients aged 12 years and older was generally similar to that of the adult population in SWIFT‑1 and SWIFT‑2 [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ), Clinical Studies ( 14 )] .
The safety and effectiveness of EXDENSUR have not been established in pediatric patients younger than 12 years of age.
🧓 Geriatric Use ▾
8.5Geriatric Use Of the 501 patients with asthma treated with EXDENSUR, 133 (27%) were 65 years of age and older and 22 (4%) were 75 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients.
🆘 Overdosage ▾
10 OVERDOSAGE If an overdosage occurs, the patient should be treated supportively with appropriate monitoring as necessary. Consider contacting the Poison Help line (1‑800‑222‑1222) or a medical toxicologist for additional overdose management recommendations.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Depemokimab‑ulaa is an IL‑5 antagonist (humanized IgG1 kappa monoclonal antibody), which binds to IL‑5 with a dissociation constant of 10.5 pM, inhibiting the bioactivity of IL‑5 with in vitro IC50 value of 4 pM by blocking its binding to the alpha chain of the IL‑5 receptor complex expressed on the cell surface. Depemokimab‑ulaa contains a triple amino acid substitution (YTE) in the fragment crystallizable (Fc) region which increases binding to the neonatal Fc receptor and thereby extends the elimination half‑life.
These properties support the dosing interval of every 6 months. IL‑5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Inflammation is an important component in the pathogenesis of asthma.
Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation. Depemokimab‑ulaa, by inhibiting IL‑5 signaling, reduced the production and survival of eosinophils; however, the mechanism of depemokimab‑ulaa action in asthma has not been definitively established.
12.2Pharmacodynamics In placebo‑controlled studies involving adult and pediatric patients aged 12 years and older with asthma, a 100 mg dose of EXDENSUR administered subcutaneously every 6 months for 52 weeks reduced blood eosinophils to a geometric mean count of 57 cells/mcL (95% CI: 51, 63) at Week 52. This corresponded to a geometric mean reduction of 79% (95% CI: 75.8, 81.8) compared to placebo. This magnitude of blood eosinophil reduction was observed within 2 weeks of treatment (at the first assessment) and was maintained throughout the treatment period.
12.3Pharmacokinetics The pharmacokinetics of depemokimab‑ulaa were approximately dose‑proportional in patients with asthma following subcutaneous administration over a dose range of 0.1‑times the recommended dose to 3‑times the recommended dose. After subcutaneous administration of 100 mg of EXDENSUR every 6 months in patients with severe asthma, the mean (standard deviation [SD]) model‑based estimated trough concentration of depemokimab‑ulaa at Week 26 was approximately 1.30 (0.44) mcg/mL. The mean (SD) model‑based estimated average steady‑state plasma concentration over a single dosing interval was 6.16 (1.62) mcg/mL.
Absorption Depemokimab‑ulaa median T max was approximately 14 days. There was no accumulation following repeat subcutaneous administration once every 6 months. Distribution The estimated typical apparent volume of distribution is
6.3L. Elimination The estimated mean (SD) elimination half‑life was 48 (4.7) days following subcutaneous administration of EXDENSUR. The estimated typical apparent clearance was 0.092 L/day.
Metabolism: Depemokimab‑ulaa is a monoclonal antibody which is expected to be metabolized into small peptides and amino acids by catabolic pathways. Specific Populations No clinically significant differences in the pharmacokinetics of depemokimab‑ulaa were observed based on age (12 to 93 years), sex, race (73% White, 7% Black, 19% Asian), body weight (34.6 to 161 kg), renal impairment (eGFR ≥90 mL/min/1.73 m 2 [normal, N = 548]; eGFR 60 to <90 mL/min/1.73 m 2 [mild, N = 380]; eGFR 30 to <60 mL/min/1.73 m 2 [moderate, N = 31], and eGFR ≤30 mL/min/1.73 m 2 [severe, N = 2]), or baseline hepatic function biomarkers (alanine aminotransferase [ALT; 5 to 153 IU/L], aspartate aminotransferase [AST; 9 to 115 IU/L], and bilirubin [1.7 to 42 microM/L]).
Pediatric Patients: There are limited pharmacokinetic data available in the pediatric population. The pharmacokinetics of depemokimab‑ulaa in pediatric patients aged 12 to 17 years were consistent with adults. The pharmacokinetics of depemokimab‑ulaa have not been studied in pediatric patients aged less than 12 years.
Drug Interaction Studies No drug interaction studies have been conducted.
12.6Immu… [Excerpted — this section continues on DailyMed.]
🧬 Mechanism of Action ▾
12.1Mechanism of Action Depemokimab‑ulaa is an IL‑5 antagonist (humanized IgG1 kappa monoclonal antibody), which binds to IL‑5 with a dissociation constant of 10.5 pM, inhibiting the bioactivity of IL‑5 with in vitro IC50 value of 4 pM by blocking its binding to the alpha chain of the IL‑5 receptor complex expressed on the cell surface. Depemokimab‑ulaa contains a triple amino acid substitution (YTE) in the fragment crystallizable (Fc) region which increases binding to the neonatal Fc receptor and thereby extends the elimination half‑life.
These properties support the dosing interval of every 6 months. IL‑5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Inflammation is an important component in the pathogenesis of asthma.
Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation. Depemokimab‑ulaa, by inhibiting IL‑5 signaling, reduced the production and survival of eosinophils; however, the mechanism of depemokimab‑ulaa action in asthma has not been definitively established.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied EXDENSUR (depemokimab‑ulaa) injection is a sterile, preservative‑free, colorless, yellow to brown, clear to opalescent solution for subcutaneous use. The syringe is not made with natural rubber latex. EXDENSUR injection is supplied as described in Table 4 .
Table 4. EXDENSUR Injection Package Configuration Package Configuration Strength NDC 1 single‑dose, prefilled syringe with attached 29‑gauge, half‑inch needle with needle guard in a carton 100 mg/mL 0173‑0927‑42 Storage and Handling Store refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not freeze.
Do not shake. Avoid exposure to heat. The prefilled syringe can be removed from the refrigerator and kept in the unopened carton, protected from light for up to 7 days at room temperature up to 86°F (30°C).
Discard if left out of the refrigerator for more than 7 days. The prefilled syringe must be administered within 8 hours once removed from the carton. Discard if not administered within 8 hours.
📋 Description ▾
11 DESCRIPTION Depemokimab‑ulaa is an interleukin‑5 (IL‑5) antagonist monoclonal antibody (humanized immunoglobulin G1 [IgG1] kappa). Depemokimab‑ulaa is produced by recombinant DNA technology in Chinese hamster ovary cells. The estimated molecular weight of depemokimab‑ulaa is 149 kDa.
EXDENSUR (depemokimab‑ulaa) injection is a sterile, preservative‑free, colorless, yellow to brown, clear to opalescent solution for subcutaneous use. EXDENSUR injection is supplied in a single‑dose, 1‑mL, prefilled syringe with a fixed 29‑gauge, half‑inch needle with a needle guard. Each 1 mL delivers 100 mg depemokimab‑ulaa, (8.43 mg) arginine HCl, (0.017 mg) edetate disodium, (1.41 mg) histidine, (2.29 mg) L‑histidine HCl monohydrate, (0.20 mg) polysorbate 80, (61.6 mg) trehalose, and Water for Injection with a pH of 6.0.
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA‑approved patient labeling (Patient Information). Hypersensitivity Reactions Inform patients of hypersensitivity reactions, including anaphylaxis, that can occur following administration of EXDENSUR. Instruct patients to contact their healthcare provider if they experience symptoms of a hypersensitivity reaction [see Warnings and Precautions ( 5.1 )] .
Acute Asthma Symptoms or Deteriorating Disease Inform patients that EXDENSUR does not treat acute asthma symptoms or acute exacerbations. Advise patients to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with EXDENSUR [see Warnings and Precautions ( 5.2 )] . Risk Associated With Abrupt Reduction of Corticosteroid Dosage Advise patients to not abruptly discontinue systemic or inhaled corticosteroids after initiation of EXDENSUR therapy.
Inform patients that reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy. Inform patients that reductions in corticosteroid dose, if appropriate, should be gradual and performed under the supervision of a healthcare provider [see Warnings and Precautions ( 5.3 )]. EXDENSUR Exposure to Fetus or Infants During Pregnancy Advise patients that the potential clinical impact of prolonged and increased EXDENSUR exposure in infants that were exposed in utero is unknown.
Inform providers of infants exposed to EXDENSUR in utero of the potential for the infant to be exposed to elevated levels of EXDENSUR for a prolonged period [see Use in Specific Populations ( 8.1 )] . Advise patients who are exposed to EXDENSUR during pregnancy to contact GlaxoSmithKline at 1‑888‑825‑5249. Trademarks are owned by or licensed to the GSK group of companies.
Manufactured by GlaxoSmithKline LLC 2929 Walnut Street, Suite 1700 Philadelphia, PA 19104 U.S. License No. 1727 Distributed by GlaxoSmithKline Durham, NC 27701 ©2026 GSK group of companies or its licensor.
EXD:2PI
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics The pharmacokinetics of depemokimab‑ulaa were approximately dose‑proportional in patients with asthma following subcutaneous administration over a dose range of 0.1‑times the recommended dose to 3‑times the recommended dose. After subcutaneous administration of 100 mg of EXDENSUR every 6 months in patients with severe asthma, the mean (standard deviation [SD]) model‑based estimated trough concentration of depemokimab‑ulaa at Week 26 was approximately 1.30 (0.44) mcg/mL. The mean (SD) model‑based estimated average steady‑state plasma concentration over a single dosing interval was 6.16 (1.62) mcg/mL.
Absorption Depemokimab‑ulaa median T max was approximately 14 days. There was no accumulation following repeat subcutaneous administration once every 6 months. Distribution The estimated typical apparent volume of distribution is
6.3L. Elimination The estimated mean (SD) elimination half‑life was 48 (4.7) days following subcutaneous administration of EXDENSUR. The estimated typical apparent clearance was 0.092 L/day.
Metabolism: Depemokimab‑ulaa is a monoclonal antibody which is expected to be metabolized into small peptides and amino acids by catabolic pathways. Specific Populations No clinically significant differences in the pharmacokinetics of depemokimab‑ulaa were observed based on age (12 to 93 years), sex, race (73% White, 7% Black, 19% Asian), body weight (34.6 to 161 kg), renal impairment (eGFR ≥90 mL/min/1.73 m 2 [normal, N = 548]; eGFR 60 to <90 mL/min/1.73 m 2 [mild, N = 380]; eGFR 30 to <60 mL/min/1.73 m 2 [moderate, N = 31], and eGFR ≤30 mL/min/1.73 m 2 [severe, N = 2]), or baseline hepatic function biomarkers (alanine aminotransferase [ALT; 5 to 153 IU/L], aspartate aminotransferase [AST; 9 to 115 IU/L], and bilirubin [1.7 to 42 microM/L]).
Pediatric Patients: There are limited pharmacokinetic data available in the pediatric population. The pharmacokinetics of depemokimab‑ulaa in pediatric patients aged 12 to 17 years were consistent with adults. The pharmacokinetics of depemokimab‑ulaa have not been studied in pediatric patients aged less than 12 years.
Drug Interaction Studies No drug interaction studies have been conducted.
🧬 Pharmacodynamics ▾
12.2Pharmacodynamics In placebo‑controlled studies involving adult and pediatric patients aged 12 years and older with asthma, a 100 mg dose of EXDENSUR administered subcutaneously every 6 months for 52 weeks reduced blood eosinophils to a geometric mean count of 57 cells/mcL (95% CI: 51, 63) at Week 52. This corresponded to a geometric mean reduction of 79% (95% CI: 75.8, 81.8) compared to placebo. This magnitude of blood eosinophil reduction was observed within 2 weeks of treatment (at the first assessment) and was maintained throughout the treatment period.
🔬 Clinical Studies ▾
14 CLINICAL STUDIES The efficacy of EXDENSUR for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype was evaluated in 2 replicate, randomized (2:1 to EXDENSUR or placebo), double‑blind, parallel‑group, placebo‑controlled, multicenter clinical trials (SWIFT‑1 [NCT04719832] and SWIFT‑2 [NCT04718103]) of 52 weeks duration. The trials enrolled adult and pediatric patients aged 12 years and older with asthma characterized by an eosinophilic phenotype, defined as a blood eosinophil count ≥150 cells/mcL at screening or ≥300 cells/mcL documented in the year prior to study entry.
Patients were required to have 2 or more asthma exacerbations requiring treatment with systemic corticosteroids (SCS) in the prior year while on background asthma therapy consisting of a medium‑ to high‑dose inhaled corticosteroids (ICS) plus at least one additional asthma controller with or without maintenance oral corticosteroids (OCS). Patients were also required to have reduced lung function at baseline (pre‑bronchodilator forced expiratory volume in 1 second [FEV 1 ] <80% predicted normal in adults; FEV 1 <90% or FEV 1 to forced vital capacity ratio <0.8 in pediatric patients aged 12 years and older).
Patients were enrolled without requiring a minimum baseline Asthma Control Questionnaire‑5 (ACQ‑5) score. In these trials, EXDENSUR 100 mg was administered subcutaneously once every 6 months for a total of 2 doses in addition to background asthma therapy. The efficacy population consisted of 762 patients who received at least 1 dose of EXDENSUR 100 mg or placebo in SWIFT‑1 (N = 382) and SWIFT‑2 (N = 380).
The demographics and baseline characteristics of the efficacy population in SWIFT‑1 and SWIFT‑2 are provided in Table 2 . Table 2. Demographics and Baseline Characteristics of Adult and Pediatric Patients Aged 12 Years and Older With Severe Asthma in SWIFT-1 and SWIFT-2 FEV 1 = forced expiratory volume in 1 second; ICS = inhaled corticosteroid; IgE = immunoglobulin E; LABA = long‑acting beta agonist; LAMA = long‑acting muscarinic antagonist; mcL = microliter; N = number of patients in the efficacy population; n = number of patients in the respective group; OCS = oral corticosteroid; SD = standard deviation; U = units. a Medium ICS dose = 440 mcg fluticasone propionate (FP) daily or equivalent; High ICS dose >440 mcg FP daily or equivalent.
SWIFT ‑ 1 N = 382 SWIFT ‑ 2 N = 380 Age (years), n (%) 12‑17 8 (2) 22 (6) 18‑64 276 (72) 262 (69) ≥65 98 (26) 96 (25) Mean (SD) 54 (14.2) 53 (16.2) Female, n (%) 223 (58) 241 (63) Race, n (%) White 316 (83) 272 (72) Asian 58 (15) 75 (20) Black or African American 8 (2) 28 (7) Other 0 5 (1) Hispanic or Latino, n (%) 23 (6) 65 (17) Never smoked, n (%) 288 (75) 294 (77) Duration of asthma (years), mean (SD) 22 (16.2) 25 (18.5) Pre‑bronchodilator % predicted FEV 1 , mean (SD) 62 (15.2) 62 (15.9) % reversibility, mean (SD) 17 (15.3) 18 (17.4) Eosinophil count (cells/mcL), median (min; max) 310 (20; 2,360) 340 (10; 4,440) Exacerbations in previous year, mean (SD) 2.2 (0.7) 2.7 (1.9) High‑dose ICS use, n (%) a 203 (53) 226 (59) ICS + LABA + LAMA use, n (%) 95 (25) 127 (33) Maintenance OCS use, n (%) 21 (5) 19 (5) Total IgE (U/mcL), median (min; max) 185 (2; 12,142) 180 (2; 16,199) Exacerbations The primary efficacy endpoint for SWIFT‑1 and SWIFT‑2 was the annualized rate of clinically significant exacerbations over the 52‑week treatment period.
A clinically significant exacerbation was defined as worsening of asthma requiring use of SCS such as intravenous or oral steroids for at least 3 days or a single intramuscular corticosteroid dose and/or hospitalization and/or Emergency Department visit. For patients on maintenance SCS, at least double the existing maintenance dose for at least 3 days was required. All patients experiencing an exacerbation were treated with SCS.
In SWIFT‑1 and SWIFT‑2, the annualized rate of asthma exacerbations was significantly lower in patients receiving EXDENSU… [Excerpted — this section continues on DailyMed.]
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No genotoxicity or carcinogenicity studies have been conducted. Male and female fertility were unaffected based upon no adverse histopathological findings in the reproductive organs from cynomolgus monkeys receiving subcutaneous dosages up to 100 mg/kg depemokimab‑ulaa for 6 months. Mating and reproductive performance were unaffected in male and female CD‑1 mice receiving an analogous antibody, which inhibits the activity of murine IL‑5.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No genotoxicity or carcinogenicity studies have been conducted. Male and female fertility were unaffected based upon no adverse histopathological findings in the reproductive organs from cynomolgus monkeys receiving subcutaneous dosages up to 100 mg/kg depemokimab‑ulaa for 6 months. Mating and reproductive performance were unaffected in male and female CD‑1 mice receiving an analogous antibody, which inhibits the activity of murine IL‑5.
📄 Patient Package Insert ▾
PATIENT INFORMATION EXDENSUR [Ex ‑ DEN ‑ shur] (depemokimab ‑ ulaa) injection, for subcutaneous use What is EXDENSUR? • EXDENSUR is a prescription medicine: o for the add‑on maintenance treatment of severe asthma in people 12 years and older whose asthma is not controlled with their current medicines. ▪ EXDENSUR helps prevent severe asthma attacks (exacerbations). ▪ EXDENSUR is not used to treat sudden breathing problems that occur with asthma. Tell your healthcare provider if your asthma does not get better or if it gets worse after you start treatment with EXDENSUR. • EXDENSUR works by targeting inflammation that plays a major role in severe asthma.
EXDENSUR reduces blood eosinophils. Eosinophils are a type of white blood cells that may contribute to your disease. It is not known if EXDENSUR is safe and effective in children with asthma under 12 years of age.
Before using EXDENSUR, tell your healthcare provider about all of your medical conditions, including if you: • are taking systemic or inhaled corticosteroid medicines. Do not change or stop taking your corticosteroid medicines unless instructed by your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine to come back. • have a parasitic (helminth) infection. • are pregnant or plan to become pregnant.
Babies exposed to EXDENSUR before birth may have higher and longer‑lasting levels of the medicine in their bodies. It is not known if EXDENSUR may harm your unborn baby. If you become pregnant while taking EXDENSUR contact GlaxoSmithKline at 1‑888‑825‑5249. • are breastfeeding or plan to breastfeed.
You and your healthcare provider should decide if you will use EXDENSUR and breastfeed. You should not do both without talking with your healthcare provider first. • Tell your healthcare provider about all the medicines you take, including prescription and over‑the‑counter medicines, vitamins, and herbal supplements. • Do not change or stop taking your other medicines unless instructed to do so by your healthcare provider. How EXDENSUR is given: A healthcare provider will inject EXDENSUR under your skin (subcutaneously) every 6 months.
If you miss a dose of EXDENSUR, contact your healthcare provider to get your next dose as soon as you can. What are the possible side effects of EXDENSUR? EXDENSUR can cause serious side effects including: • allergic (hypersensitivity) reactions, including anaphylaxis.
Serious allergic reactions can happen after you get your EXDENSUR injection. Contact your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction: ○ swelling of your face, mouth, and tongue ○ fainting, dizziness, feeling lightheaded (low blood pressure) ○ hives ○ breathing problems ○ rash The most common side effects of EXDENSUR include: • upper respiratory tract infection (common cold, sinus infection) • sneezing, nasal congestion, runny nose, and nasal itching (allergic rhinitis) • flu or flu‑like symptoms • joint pain • sore throat (pharyngitis) These are not all of the possible side effects of EXDENSUR.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088. General information about the safe and effective use of EXDENSUR.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about EXDENSUR that is written for health professionals. What are the ingredients in EXDENSUR?
Active ingredients: depemokimab‑ulaa Inactive ingredients: arginine HCl, edetate disodium, histidine, L‑histidine HCl monohydrate, polysorbate 80, trehalose, Water for Injection. For more information about EXDENSUR, call 1‑833‑EXDENSUR or visit our website at www.EXDENSUR.com . Trademarks are owned by or licensed to the GSK group of companies.
Manufactured by: GlaxoSmithKline LLC, Philadelphia, PA 19104, U.S. License No. 1727 Distrib… [Excerpted — this section continues on DailyMed.]
📄 Recent Major Changes ▾
Dosage and Administration, Preparation and Administration Instructions for EXDENSUR ( 2.2 ) 06/2026
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL NDC 0173-0927-42 EXDENSUR (depemokimab-ulaa) Injection Rx Only GSK 100 mg/mL For subcutaneous use Prefilled Syringe Contents: - 1 Single-Dose 1-mL Prefilled Syringe - Prescribing Information - Patient Information ©2025 GSK group of companies or its licensor. Rev. 12/25 62000000099386 Exdensur 100 mg per mL Syringe Carton
Medicare Part D spend CMS · PART D · 2026 (Q1)
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |